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Abstract
The chapter will focus on the different aspects of nonalcoholic fatty liver 
disease (NAFLD). An update in noninvasive MR-based imaging will be offered 
in detail, pointing mainly to fat, iron, and fibrosis deposition and the accuracy of 
quantitative methods in disease grading and severity assessment. NAFLD is the 
most common cause of chronic liver disease (CLD) in Western countries. MRI is 
used to evaluate the disease, to assess the severity, and to quantify the amount of fat 
deposition, being also the method of choice to evaluate and quantify iron overload. 
Diagnosis and staging of liver fibrosis is one of the most challenging aspects of non-
invasive imaging. “Virtual biopsy” refers to the possibility of imaging techniques to 
depict, map, and measure fibrosis minimizing the need for invasive liver biopsies in 
CLD. MRI allows an accurate determination of steatosis, iron overload, and fibrosis, 
even if they coexist.
Keywords: steatosis, fibrosis, iron overload, contrast-enhanced MRI, 
chemical shift sequences
1. Introduction
1.1 The importance of noninvasive evaluation of liver steatosis and  
fibrosis in NAFLD patients
NAFLD is currently the most common cause of CLD worldwide. It is defined 
by lipid droplet accumulation within hepatocytes in the absence of substantial 
alcohol intake. NAFLD comprises a disease spectrum ranging from simple steatosis 
to nonalcoholic steatohepatitis (NASH), which may progress into liver fibrosis 
and even end-stage cirrhosis [1]. NAFLD is becoming a major concern with the 
increasing incidence of obesity in Europe. Available data suggest that the global 
prevalence of NAFLD is estimated at 24%, being the leading cause of CLD in the 
USA and Europe [2].
The differentiation of simple steatosis from NASH has a great clinical impor-
tance. Additionally to liver steatosis, NASH presents inflammation and hepatocel-
lular injury [3]. The differentiation between both entities is routinely made by 
histopathological analysis after liver biopsy. However, it is an invasive method, with 
inherent risks that include sampling error and serious complications [4].
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Currently, there is an urgent need for a noninvasive method to accurately assess 
liver fibrosis and liver steatosis. Ultrasonography (US)-based and computer tomogra-
phy (CT)-based modalities can demonstrate the morphologic alterations of  cirrhosis, 
but they are limited in evaluating patients with earlier stages of liver disease [5].
Advancements in magnetic resonance imaging (MRI), with its unique and 
intrinsic imaging features, have provided the opportunity to revolutionize how 
we image and evaluate patients with diffuse liver diseases. In addition, with the 
development of new antifibrotic therapeutic agents, MRI-based techniques may 
play a central role in monitoring treatment response and in the clinical management 
of patients with NAFLD [6, 7].
The recent technical developments in MRI hardware and software,  including 
the use of three Tesla MR devices in daily routine work, have significantly 
improved the temporal and spatial resolutions, especially in the case of contrast-
enhanced T1-weighted 3D sequences. The use of various liver-specific hepato-
biliary contrast agents enables not only morphological characterization but also 
a functional assessment of all liver lesions and also characterization of diffuse 
parenchymal changes [8].
2. Liver biopsy: the available but imperfect gold standard
Currently, liver biopsy is the reference standard for the diagnosis and staging 
of liver fibrosis [4]. However, this procedure has several major limitations, includ-
ing its invasive nature, risk for potential complications, poor patient acceptance, 
interobserver variability, and possible sampling errors [4, 9].
Liver biopsy captures only a tiny fraction of the liver (roughly 1/50.000), 
leading to sampling errors [10]. In an attempt to reduce sampling variability, it is 
recommended that liver biopsy specimens be at least 2.0 cm long and contain at 
least 11 portal triads. Biopsy specimens that do not meet these criteria are associated 
with a high risk of under staging (false negative) [11].
In contrast to fibrosis in chronic viral hepatitis, fibrosis in alcoholic hepatitis and in 
the adult form of NAFLD begins adjacent to the central veins. The fibrosis is laid down 
in a perisinusoidal manner, and the scar tissue surrounds individual hepatocytes. As 
the disease advances, perisinusoidal fibrosis accumulates adjacent to portal tracts, and 
the fibrotic tissue eventually coalesces into fibrous bridges connecting portal triads 
and central veins, ultimately culminating in cirrhosis [3]. As cirrhosis develops, the 
characteristic histologic features of fatty liver disease may be lost. The perisinusoidal 
may no longer be apparent, and other features (e.g., inflammatory cells, ballooned 
hepatocytes, and steatosis) may subside. Thus, cirrhosis due to fatty liver disease may 
be indistinguishable from cirrhosis due to viral hepatitis or other causes [12].
3. MRI-based methods for the noninvasive diagnosis of NAFLD
The search for the best diagnostic technique in terms of noninvasiveness and 
accuracy is still a major concern in recent research activity. In the recent literature, 
the role of several imaging diagnosis tools and specific contrast agents is reported in 
the evaluation of diffuse liver diseases such as steatosis, fibrosis, and cirrhosis.
The differentiation of prognostically relatively benign simple steatosis from 
potentially progressive NASH is a crucial issue [13, 14]. Moreover, NAFLD is a 
reversible condition, especially during the early onset of the disease; therefore 
diagnosing and correct staging of patients with NAFLD are essential in order to 
prevent the development of an irreversible advanced liver disease.
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Routine biochemical laboratory tests and conventional imaging, including US, 
CT, and non-specific gadolinium-enhanced MRI, cannot distinguish between these 
entities with sufficient confidence [15, 16]. Therefore, the differentiation between 
both entities is routinely made by histopathological analysis after liver biopsy. 
Liver biopsy is still considered the reference standard for the diagnosis of NASH 
[4]. There are several histological scoring systems to grade NASH, and the most 
commonly used is the so-called NAFLD activity score (NAS) [17]. The steatosis 
activity and fibrosis score (SAF) are a newly developed system for categorizing liver 
histology in NAFLD patients [18]. The lack of reliable, noninvasive methods for the 
diagnosis of disease severity and prediction of prognosis is one of the major draw-
backs in the clinical management of patients with NAFLD [19].
3.1 The diagnostic value of MR imaging techniques in assessing NAFLD
3.1.1 Magnetic resonance elastography
Magnetic resonance elastography (MRE) assesses viscoelastic properties of soft 
tissues [20], offering a direct insight into the liver parenchymal stiffness. First step 
in the MRE technique is generating mechanical waves in the liver tissue. Then gra-
dient-echo sequences are used to image wave motion, while a specialized software 
utilizing inversion algorithms transforms the images obtained into elastograms, 
revealing the tissues’ stiffness quantitative map, expressed in kilopascals [21].
Studies comparing healthy volunteers and patients with CLD established that 
the shear viscoelastic parameters of the liver increased according to the stage of 
liver fibrosis, and a statistically significant difference between the patients with 
Metavir scores F0–F1 fibrosis versus F2–F3, F2–F3 versus F4, and F0–F1 versus F4 
was found [20, 22]. MRE also proved to be superior to biochemical testing using 
the aspartate aminotransferase-to-platelet ratio index [22]. Most importantly the 
authors could clearly separate the intermediate fibrosis stages, using MRE elasticity 
measurements.
Chen et al. [23] demonstrated that MRE-based assessments of liver stiffness in 
patients with NAFLD may have a high diagnostic accuracy (AUC 0.93) for discrimi-
nating NASH from simple steatosis, with a cutoff value of 2.74 kPa reaching 94% 
sensitivity and 73% specificity. However, a more recent study suggested that the 
performance of MRE for diagnosis of NASH versus simple steatosis was rather mod-
est and did not provide a high level of accuracy. Using 2D-MRE (60 Hz), 3D-MRE 
(60 Hz), and 3D-MRE (40 Hz), the AUROC for diagnosing definite NASH was 
0.754, 0.757, and 0.736, respectively [24].
In a prospective study, Cui et al. [25] proved that the diagnostic accuracy of 
2D-MRE for the noninvasive evaluation of advanced fibrosis in patients with 
biopsy-proven NAFLD was significantly higher than five clinical prediction rules, 
widely validated for the assessment of fibrosis in patients with NAFLD, such as the 
NAFLD fibrosis score, the BARD score, the AST-to-ALT ratio, FIB-4, and AST-to-
platelet ratio index. Using the cutoff value for 2D-MRE of 3.64 kPa, the AUROC of 
2D-MRE for predicting advanced fibrosis was 0.957. This proved to be significantly 
higher than FIB-4 score with AUROC of 0.861, the best-of-all analyzed clinical 
prediction rules. Therefore, 2D-MRE is a promising noninvasive imaging-based bio-
marker for the diagnosis of advanced fibrosis in NAFLD patients used additionally 
to clinical prediction rules, especially when the latter have indeterminate values.
The cutoff values proposed by Loomba et al. [26] for the prediction of each 
fibrosis stage using 2D-SWE in patients with NAFLD were 3.02 kPa for early 
fibrosis, 3.58 kPa for significant fibrosis, 3.64 kPa for advanced fibrosis, and 
4.67 kPa for the prediction of cirrhosis, with areas under the ROC curve of 0.838, 
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0.856, 0.924, and 0.894, respectively. The most promising results were obtained for 
discriminating advanced fibrosis (F3–F4) from fibrosis stages 0–2 with a sensitivity 
of 0.86 (95% confidence interval [CI]: 0.65–0.97) and a specificity of 0.91 (95% CI, 
0.83–0.96).
Kim et al. showed, however, that the best cutoff for detecting advanced fibrosis 
value was 4.15 kPa (AUROC = 0.954, sensitivity = 85%, specificity = 92%). The 
performance of this technique for discriminating between other fibrosis stages was 
also satisfactory [27].
Nevertheless, this ability to stage pre-cirrhotic disease could make MRE very 
useful for the assessment of therapeutic success and disease progression [28].
More advanced versions of the imaging modality such as 3D-MRE allow the 
evaluation of a larger volume of liver parenchyma than 2D-MRE, being significantly 
more accurate for diagnosis of advanced fibrosis in NAFLD patients [24].
As it is not affected by the absence of an ultrasound window, MRE is more 
precise than ultrasonographic elastographic techniques. In patients with obesity to 
morbid obesity, MRE proved to have a better success rate than vibrant-controlled 
transient elastography (95.8 versus 81.3%) and a higher interobserver agreement 
than liver biopsy (intraclass correlation coefficient, 0.95 versus 0.89) [29].
Acute inflammation, passive liver congestion caused by cardiac insufficiency, 
or obstructive cholestasis leads to a false increase of liver stiffness values [30]. 
Moreover, on a gradient-echo MRE sequence, certain conditions such as iron 
overload states may lead to a lower MRI signal intensity, which does not allow shear 
wave recognition. This leads to a decrease in MRE diagnostic accuracy. Thus, using 
spin-echo or echo-planar sequences with lower T2* effect susceptibility can alleviate 
this problem [30].
The technique has the advantage of not being influenced by the patient’s weight 
or the presence of ascites. MRE remains expensive and not widely accessible in the 
everyday imaging routine of patients with NAFLD.
3.1.2 Magnetic resonance spectroscopy
MR spectroscopy (MRS) enables the noninvasive measurement of concentra-
tions of different chemical components within tissues, which are displayed as a 1D 
spectrum with peaks consistent with the various chemicals detected. The major 
problem in obtaining MRS signals from abdominal organs is sensitivity to physi-
ologic movement during the scan time usually exceeding several minutes [31]. 
Usually, the measurement is performed by manually placing a single voxel into the 
liver parenchyma far from the liver capsule, in an area free of large vessels or bile 
ducts [32].
While proton MRS is a very useful technique for the quantification of hepatic 
fat, its use for the estimation of hepatic fibrosis appears to be limited [33, 34].
According to Abrigo et al. [34], phosphorus-MRS (31P-MRS) shows distinct 
biochemical changes in different NAFLD states and has fair diagnostic accuracy 
for NASH. However, this technique requires considerable operator skills (sequence 
programming, shimming, analysis of spectra) and access to special equipment 
(scanner, 31P coil) [28].
31P-MRS permits in vivo evaluation of energy metabolism and intracellular 
compartment division through different signals and provides metabolic informa-
tion, which is useful when assessing fibrogenesis [28]. A significant correlation 
between phosphodiester concentration and the stage of fibrosis and a correlation 
between “anabolic charge” (phosphomonoester/[phosphomonoester + phosphodi-
ester]) and the stage of fibrosis were found in a study comparing a group of patients 
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with steatosis and no to moderate inflammation to a group of patients with severe 
fibrosis or cirrhosis [35].
Hydrogen 1 MRS (1H-MRS) has proven its efficiency in quantifying liver 
steatosis, by measuring lipid peaks, identified in the liver at 0.9, 1.3, 2.0, 2.2, and 5.3 
parts per million. The dominant lipid peaks are caused by the resonance of methyl 
(-CH3) protons and methylene (-CH2) in the triglyceride molecule [36].
The absolute fat concentration can be therefore calculated using the following 
formula:
 Triglyceride content =  total lipid peak area / (total lipid resonance peak + water 
resonance peak) (1)
As the steatosis grade increases, the size of the lipid peaks relative to the water 
peak increases as well [36].
The advantages of 1H-MRS are the very high sensitivity, a good correlation 
with histological analysis, and the method’s independency of confounders such as 
fibrosis and iron or glycogen depositions. On the other side, MRS has currently a 
limited clinical availability, and it is prone to sampling error, when a single-voxel 
liver spectroscopy is performed [36].
Furthermore, authors assessed the diagnostic accuracy of a novel magnetic reso-
nance protocol for liver tissue characterization, using T1 mapping, 1H spectroscopy, 
and T2* mapping, which quantified liver fibrosis, steatosis, and hemosiderosis, 
respectively [37]. According to their results, the novel scanning method provides 
high diagnostic accuracy for the assessment of all three histology variables.
In a recent study, Idilman et al. [38] analyzed the efficiency of MRI-proton 
density fat fraction (MRI-PDFF) and MRS-determined liver fat content in patients 
with NAFLD in comparison with liver biopsy-determined steatosis.
No superiority between the two imaging methods was observed. This study 
emphasized that the estimation of fat liver content using both MR imaging techniques 
was more accurate in the absence of liver fibrosis. MRS showed promising results for 
discriminating moderate/severe steatosis from none/mild steatosis with an AUROC of 
0.857. A cutoff value of 9% provided a sensitivity of 92%, negative predictive value of 
83.3%, specificity of 71%, and positive predictive value of 84.6%.
The accurate assessment of liver fat content in patients with NAFLD is essential 
in identifying those who are at greater risk of progressing into advanced fibrosis 
stages, being also of great value in evaluating the response to therapy. Liver steatosis 
also influences the successful rate of liver transplantation (LT); one of the necessary 
requirements in many centers is that the living donor liver must not exceed 5% steato-
sis, as greater values are associated with increased recipient liver dysfunction [38].
MRS proves to be a highly accurate noninvasive technique, which allows us to 
distinguish between individuals with simple steatosis and steatohepatitis who may 
benefit from early intervention and more aggressive therapy.
3.1.3 Diffusion-weighted MR imaging
Diffusion-weighted imaging (DWI) is a noninvasive method that allows mea-
surement of the microscopic motion of water in tissue and generates representative 
apparent diffusion coefficient (ADC) values. DWI uses very fast scans with an 
additional series of (diffusion) gradients rapidly turned on and off [28].
Within tissues with highly cellular component and therefore a narrowed extra-
cellular space, the water molecule motion is impeded leading to restricted water 
diffusion in such tissues. In contrast, fluid-rich or necrotic structures are associated 
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with a greater freedom of motion of water molecules, and the water diffusion in 
such tissues is considered to be “free.” Therefore, on DWI sequences, the signal 
intensity reflects the tissue diffusion characteristics, which is influenced by cellular-
ity and the integrity of cell membranes [39].
In a prospective study, Guiu et al. [40] demonstrated that both pure molecular 
diffusion and perfusion-related diffusion were significantly lower in the steatotic 
liver than in the normal liver. On a group of 89 NAFLD patients who underwent 
liver biopsy, Murphy et al. [41] also found a good correlation between histologic 
features of NAFLD liver and DWI-derived quantitative measures. Molecular diffu-
sivity was significantly decreased with steatosis, while perfusion fraction decreased 
with fibrosis degree. Same associations were found between pediatric NAFLD 
histologic features and DWI parameters, with a high interobserver reproducibility 
[42]. As far as the apparent diffusion coefficient is concerned, studies show incon-
sistent results. One study in adults with NAFLD found that ADC decreased with 
steatosis, while others found no significant relationship [40, 41].
Several studies have evaluated the use of DWI and ADC values for the diagnosis 
of hepatic fibrosis or cirrhosis in patients with diffuse hepatopathies. The complex 
assembly of collagen fibers, glycosaminoglycan, and proteoglycans that constitutes 
liver fibrosis may restrict the molecular diffusion measured by DWI [43].
DWI has been successfully applied to differentiate cirrhotic from healthy tissue. 
Girometti et al. reported a positive predictive value of 100%, a negative predictive 
value of 99.9%, and an overall accuracy of 96.4% in cirrhotic patients compared to 
healthy controls [44].
A recent meta-analysis suggests that DWI parameters can reliably stage hepatic 
fibrosis, having a good diagnostic accuracy with areas under the SROC curve 
between 80 and 90%. A high b value for liver fibrosis imaging (between 800 and 
1000 s/mm2) could significantly increase the diagnostic accuracy of diffusion imag-
ing in differentiating between significant and severe fibroses (>F2). For diagnosing 
liver cirrhosis (F4), the use of 3T MRI equipment has also proved to optimize the 
DWI diagnostic accuracy, compared to 2T MRI [45].
Lewin et al. found a significant relationship between the ADC values and necro-
inflammatory scores and suspected an influence of steatosis on apparent diffusion 
coefficient values [46]. In addition, the ADC of fibrotic livers was decreased as the 
fibrosis scores increased in some studies [46], but not in others [43].
However, differences in MR equipment and sequence parameters make it difficult 
to compare studies. Clearly, more research is needed to create a standard setup for 
DWI sequence acquisition to make studies comparable and to determine whether or 
not DWI can be a useful tool for the diagnosis and staging of diffuse liver diseases.
Furthermore, DWI imaging is susceptible to artifacts (e.g., blurring, ghosting, 
and distortions) and offers a limited image quality; therefore, DWI is currently 
used as complementary and not as a replacement to conventional sequences in the 
evaluation of NAFLD [47].
DWI does not require administration of intravenous contrast; consequently 
the technique might represent a reasonable option for patients with kidney failure, 
where gadolinium-based contrast substances represent a contraindication due to 
the increased risk of developing nephrogenic systemic fibrosis, while iodinated 
CT contrast might lead to an even greater impairment of renal function, being also 
contraindicated [47].
3.1.4 Susceptibility-weighted MR imaging
It is known that, among other factors, increased iron content of the liver and 
secondary changes manifesting in progressive collagen deposition are important 
background alterations in the development of liver fibrosis [48].
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Susceptibility-weighted imaging (SWI) is well known as a three-dimensional 
(3D) gradient-echo (GRE) technique utilizing phase information to increase 
sensitivity for detecting susceptibility changes that result from, for example, iron, 
hemoglobin, and calcification. Initially used for neuroimaging [49, 50], recent 
technical advances allow for possible abdominal applications.
SWI is based on T2*-weighted GRE sequences and exploits both magnitude and 
phase information. Traditionally SWI sequences are high-resolution 3D sequences. 
Employing 3D sequences for abdominal imaging is not feasible because of long 
acquisition times and the large B0 variations encountered in this body area. With 
the advent of a multi-breath-hold GRE-sequence-based SWI, a two-dimensional 
(2D) sequence was developed for abdominal imaging [51]. SWI utilizes the differ-
ences in the magnetic susceptibilities of different tissues and produces a contrast 
superior to conventional T1- and T2-weighted MR imaging in the detection of 
structures that cause susceptibility artifacts [52].
The superiority of SWI over the T2*-weighted sequence has been shown, both 
in the detection and conspicuity of increased liver iron deposition and siderotic 
nodules [51] and in the detection of intratumoral hemorrhage in hepatocellular 
carcinoma (HCC) [53].
The liver-to-muscle signal intensity ratio on SWI proved to be a reliable mea-
surement in grading liver fibrosis in patient with diffuse liver disease, with a high-
diagnostic accuracy for the differentiation of moderate to advanced (F2 and F3)  
liver fibrosis from liver cirrhosis (F4) (AUROC = 0.93). The multiple regression 
analysis showed that liver fibrosis independently influenced SWI measurements, 
being a main contributor to the decreasing liver-to-muscle SI ratio, followed by iron 
overload and necroinflammatory activity, when compared with histopathologic 
findings [52].
The relationship between iron load and fibrogenesis has multiple consider-
ations. The increased iron content in the liver, either diffusely distributed or in 
the form of numerous siderotic nodules, does not represent the entire transforma-
tion of liver fibrosis. In the process of fibrogenesis, hepatic stellate cells are also 
activated by other factors such as inflammation, genetic determinants, and the 
immune system [52].
Using a multiparametric approach, a recent study proved that liver SWI signal 
intensity enhanced the diagnostic performance in diagnosing and staging liver 
fibrosis, when used together with the apparent diffusion coefficient of the liver 
parenchyma on DWI and the degree of liver enhancement on the hepatobiliary 
phase of dynamic contrast-enhanced MRI. The three MRI techniques used together 
were able to assess the severity of liver fibrosis with an AUC ranging from 0.90 to 0.95, 
and the best performance was obtained in predicting moderate fibrosis (F2 or 
greater), with a sensitivity of 86% and a specificity of 94%. This reflects the clinical 
significance of this diagnostic tool, as F2 or greater is the stage in which therapeutic 
action should be taken [54].
3.1.5 Proton density fat fraction
Proton density fat fraction (PDFF) measurement is a multi-echo chemical shift-
encoded MRI method for quantitatively assessing hepatic steatosis, being available 
as an option from several manufacturers of MRI scanners. PDFF is defined as the 
ratio of the density of mobile protons from triglycerides and the total density of 
protons from mobile triglycerides and mobile water. It is expressed as an absolute 
percentage (%) and ranges from 0 to 100% [7].
This sequence allows the measurement of fat fraction in any segment of the liver, 
generating a fat mapping of the entire hepatic parenchyma. This is of great value, as 
several studies proved the heterogeneous intrahepatic fat distribution [55].
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The advantages of PDFF calculation are its ability to be completely obtained 
during a short breath-hold (in less than 25 s) and the fact that it minimizes the 
errors from confounders of fat quantification encountered using conventional MRI 
methods (Dixon and fat saturation) such as T1 bias, T2* decay, or spectral complexity 
of lipid [38].
Emerging data support the use of MRI-PDFF in evaluating the response to 
treatment in the setting of early-phase clinical trials in NASH, using drugs with an 
anti-steatotic mechanism of action [7].
In a recent study, the mean fat fraction was significantly lower in the left lobe 
than it was in the right, while liver segments 4 and 5 proved to be the most adequate 
to estimate the entire hepatic lipid content [55].
Regarding technical parameters, using a six-echo map proved to have a higher 
diagnostic accuracy than three, four, or five echoes [56].
Permutt et al. showed a good correlation between MRI-PDFF and histology-
determined steatosis grade in adults with NAFLD. They observed an increasing 
average value of MRI-determined PDFF with increasing steatosis grade (8.9% for 
grade 1, 16.3% for grade 2, and 25% for grade 3 steatoses) [57]. PDFF was effective in 
differentiating moderate or severe hepatic steatosis from mild or no hepatic steatosis, 
with area under the curve of 0.95 and 93% sensitivity and 85% specificity. However, 
the correlation between biopsy and PDFF-determined steatosis was less pronounced 
when fibrosis was present (r = 0.60) than when fibrosis was absent [58].
When comparing the efficiency of MRI-PDFF to magnetic resonance spectros-
copy, both techniques proved to strongly correlate with the histology-determined 
steatosis, with no superiority between them [38]. But the PDFF maps have the advan-
tage of being automatically reconstructed without user input or post-processing, 
unlike MR spectroscopy-based methods.
Therefore, MR-PDFF represents another novel, noninvasive, and practical 
imaging tool in assessing patients with NAFLD, as the entire liver can be covered in 
assessment with a great accuracy in quantifying total hepatic fat amount [38, 55].
3.1.6 Contrast-enhanced MRI
In the liver, contrast agents are categorized into non-specific agents that 
distribute into the vascular and extravascular extracellular spaces (such as the 
linear gadopentetate dimeglumine (Gd-DTPA) and the macrocyclic gadobutrol 
(Gd-DO3A-butrol) and gadoterate dimeglumine (Gd-DOTA)) and liver-specific 
agents taken up by liver cells. These liver-specific agents are either taken up 
by Kupffer cells (such as the super paramagnetic iron oxide particles ferumox-
ides and ferucarbotran) or by hepatocytes (such as gadolinium ethoxybenzyl 
dimeglumine or gadoxetic acid (Gd-EOB-DTPA) and gadobenate dimeglumine 
(Gd-BOPTA)) [8].
3.1.6.1 Hepato-specific contrast-enhanced MRI
Gadoxetic acid (Gd-EOB-DTPA, Eovist® in the USA, Primovist® in Europe) 
is a liver-specific MRI contrast agent which provides both morphological and 
functional information and can be used as an imaging biomarker in the diagnostic 
workup of liver fibrosis [8].
After intravenous injection, the gadoxetic acid (GA) distributes into the vascular 
and extravascular spaces during the arterial, portal venous, and late dynamic phases 
and progressively into the hepatocytes and bile ducts during the hepatobiliary 
phase. GA enhancement depends mainly on liver perfusion, vascular permeability, 
extracellular diffusion, and hepatocyte transporter expression [8, 59].
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All these functions are disturbed in diffuse liver diseases, and there may be a 
decrease in the balance between uptake and excretion of the contrast media by the 
impaired hepatocytes.
The transport of GA in the hepatocytes is mediated by two different transport 
systems located at the sinusoidal and canalicular membranes of the cell [60]. The 
contrast agent enters the hepatocytes through two organic anion-transporting 
polypeptide transporters (OATP1B1 and OATP1B3) [61], and it is excreted into the 
bile via the multidrug resistance protein 2 (MRP2) [62].
In patients with liver cirrhosis, the upregulation of MRP2 is associated with 
significant signal loss on gadoxetic acid-enhanced MR images [63]. Organic acid 
efflux from hepatocytes may also occur through the sinusoidal membrane because 
the transport through OATP is bidirectional and because the sinusoidal membrane 
also contains multidrug resistance proteins (MRP3 and MRP4), as it is illustrated 
in Figure 1. These efflux pumps are normally expressed at low levels in normal 
hepatocytes but can be upregulated in pathologic conditions, such as cholestasis. 
GA is not metabolized within hepatocytes [64].
With GA, approximately 50% of the administered dose in the normal human 
liver is transported through the hepatocytes and excreted into the bile, and the 
percentage of the contrast agent that is not cleared by the hepatobiliary system is 
excreted by glomerular filtration in the kidneys [65].
Hepatobiliary MR contrast agents can be used to characterize liver functional 
properties, and the relative enhancement quantification is a reflection of 
hepatocyte malfunction as a result of liver fibrosis accumulation and increased 
necroinflammatory activity [66].
Several MR-derived parameters can be used to estimate the amount of GA 
uptake, such as the relative liver enhancement, hepatic uptake index, and T1 map-
ping during hepatobiliary phase—on static images or the hepatic extraction fraction 
and liver blood flow—by using dynamic assessment [67]. Importantly, there is cur-
rently no clear consensus as to which of these MR-derived parameters is the most 
suitable for assessing liver dysfunction.
Figure 1. 
Cellular pharmacology of Gd-EOB-DTPA—figure adapted after Van Beers et al. [8].
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The relative liver enhancement (RLE), the most commonly used parameter, is 
calculated by subtracting the signal intensity (SI) on the unenhanced images from 
the SI in the HBP, and dividing the difference by the SI of the unenhanced images, 
using the following formula [67]:
 Relative enhancement  (RE) =  (SI 20 minutes post − contrast − 
 SI pre − contrast) / SI pre − contrast (2)
In order to avoid bias due to liver parenchyma inhomogeneity, several regions of 
interest (ROI) are placed in different segments of both liver lobes.
Indeed, reports on animal models also proved that gadoxetic acid-enhanced MRI 
could differentiate simple steatosis from NASH by comparing the signal profile 
or the time of maximum relative enhancement [68]. Furthermore, several recent 
Imaging 
technique
Advantages Disadvantages
MRE • Excellent diagnostic accuracy for staging 
liver fibrosis and cirrhosis
• Uninfluenced by obesity or ascites
• Increased failure rate in iron overload 
states
• Not widely available
MRS • Excellent sensitivity for detecting mild 
steatosis
• Good correlation with histological 
analysis
• Independent of confounders (e.g., 
fibrosis, iron, glycogen)
• Requires specialized post-processing 
data, expensive
• Sensitive to field inhomogeneity
• Technical limitations: low signal-to-
noise ratio, motion
• Evaluation of small portion of the liver
DWI • Functional information in the absence of 
intravenous contrast
• Successfully applied to differentiate 
cirrhotic from healthy tissue
• Limited image quality
• Susceptible to artifacts (e.g., blurring, 
ghosting, and distortions)
• Needs further research
SWI • Iron overload quantification
• Enhances the diagnostic performance of 
other MRI techniques in diagnosing liver 
fibrosis
• Susceptibility artifacts
PDFF • The most accurate and precise imaging 
biomarker to quantify liver steatosis
• Not influenced by iron overload
• Short acquisition time
• Volumetric assessment
• Accuracy could be affected by fibrosis, 
severe steatosis
Liver-
specific 
contrast 
MRI
• Allows evaluation of both liver morphol-
ogy and function
• High sensitivity in differentiating 
between simple steatosis and NASH
• Low specificity in differentiating 
between simple steatosis and NASH
• Confounders: increased liver function 
parameters
MRE, magnetic resonance elastography; MRS, magnetic resonance spectroscopy; DWI, diffusion-weighted MR 
imaging; SWI, susceptibility-weighted MR imaging; PDFF, proton density fat fraction.
Table 1. 
Summary of main advantages and disadvantages of different MRI techniques in evaluating patients with 
NAFLD.
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studies have shown the ability of gadoxetic acid-enhanced MRI to evaluate patients 
with CLD, particularly for the staging of hepatic fibrosis, and to obtain global and 
territorial liver function information [69].
In a retrospective, proof-of-concept study, the mean relative enhancement of the 
whole liver after GA administration was significantly lower in patients with NASH 
(0.82 ± 0.22), compared to those with simple steatosis (1.39 ± 0.52) [70]. Therefore, 
the relative enhancement measurements could potentially be used to differentiate 
between simple steatosis and NASH [AUC = 0.85 (95% CI 0.75–0.91)], providing a 
high sensitivity of 97% but a low specificity of 63% [70].
Histology parameters used to stage NASH, such as lobular inflammation, hepato-
cellular ballooning, and the degree of liver fibrosis, proved to be independent factors 
that negatively correlated with RLE. On the other side, fatty liver infiltration did not 
correlate with the relative enhancement. Due to its low specificity, GA-MRI cannot 
be used at this moment as the only criterion by which to differentiate simple steatosis 
and NASH. However, GA-MRI can be used as a valuable screening tool in identifying 
which NAFLD patients need to perform liver biopsy and which do not [70].
With regard to liver fibrosis staging, the contrast enhancement index (method 
that uses the paraspinal muscles’ signal intensity as a reference for liver) proved to 
be an efficient biomarker, with higher diagnostic accuracy than other enhancement 
parameters or hematologic markers [71]. RLE is best suited for detecting moderate 
to advanced fibrosis, but the interpretation of results should consider laboratory 
parameters, with special attention to liver function. Elevated levels of aspartate 
aminotransferase, gammaglutamyl transpeptidase, and alkaline phosphatase levels 
were independent predictors of false-negative results [69].
The main advantages and disadvantages of each magnetic resonance imaging 
technique currently used in the noninvasive assessment of NAFLD are briefly 
synthetized in Table 1.
4. Conclusion
MRI is currently increasingly used in the assessment of NAFLD. Although all 
methods have their own advantages and disadvantages, the noninvasive diagnosis 
of NAFLD using innovative applications of MRI-based methods presents a promis-
ing future. Liver fibrosis can be accurately assessed using MRI methods that do 
not require contrast media administration, such as MRE, diffusion-weighted MRI, 
and susceptibility-weighted MRI, while quantitative detection of liver steatosis is 
better performed using MRS or chemical shift-based MRI techniques such as proton 
density fat fraction. Moreover, GA-enhanced MRI provides both morphological and 
functional information and can be used as an imaging biomarker in the diagnostic 
workup of liver fibrosis and may help to distinguish between the two subgroups of 
NAFLD, simple steatosis and nonalcoholic steatohepatitis.
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